Concepedia

Author

Michael Krainer

Medical University of ViennaORCID

Also Known As

Christiane Thallinger, Krainer, Michael, M Krainer, M. Krainer, MICHAEL KRAINER, Matti Aapro, Michael Krainer

206

Publications

7K

Citations

39

H-Index

62

Concepts

All Affiliations

Medical University of ViennaVienna General HospitalComprehensive Cancer Center ViennaUniversity of ViennaInstitut Gustave Roussy
MK

About

Michael Krainer is an author at Medical University of Vienna specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

32

3K

2

Cell Biology

8

8

364

3

Health Sciences

6

6

1.8K

4

Engineering

1

1

52

5

Nursing

1

1

31

Michael Krainer

×

69

Publications

5.9K

Citations

38

H-Index

YearCitations

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon, Charles G. Drake, H. I. Scher,

The Lancet Oncology

2014

1.5K

Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome

Kim E. Nichols, D. Paul Harkin, Seth Levitz,

Proceedings of the National Academy of Sciences

1998

495

Germ-Line<i>BRCA1</i>Mutations in Jewish and Non-Jewish Women with Early-Onset Breast Cancer

Michael G. FitzGerald, Deborah J. MacDonald, Michael Krainer,

New England Journal of Medicine

1996

387

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg,

Journal of Clinical Oncology

2016

244

Differential Contributions of<i>BRCA1</i>and<i>BRCA2</i>to Early-Onset Breast Cancer

Michael Krainer, Sandra Silva-Arrieta, Michael G. FitzGerald,

New England Journal of Medicine

1997

210

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

Karim Fizazi, Charles G. Drake, Tomasz M. Beer,

European Urology

2020

163

Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer

Peter Horak, Dietmar Pils, Griet Haller,

Molecular Cancer Research

2005

148

Monitoring of Serum Her-2/<b> <i>neu</i> </b> Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer

Wolfgang J. Köstler, Barbara Schwab, Christian F. Singer,

Clinical Cancer Research

2004

144

Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]

H. Ludwig, DM Nachbaur, E. Fritz,

Blood

1991

142

Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]

H Ludwig, DM Nachbaur, E Fritz,

Blood

1991

125

Page 1